Esperion Therapeutics (ESPR) Income towards Parent Company (2012 - 2026)

Esperion Therapeutics has reported Income towards Parent Company for 15 years, with the latest figure at -$26.4 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 36.48% year-over-year to -$26.4 million; the trailing twelve-month figure through Mar 2026 stood at -$9.2 million (up 91.86% YoY), and the FY2025 full-year result was -$22.7 million, up 56.17% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$26.4 million, down from $62.6 million in the prior quarter.
• The five-year high for Income towards Parent Company was $62.6 million in Q4 2025, with the low at -$66.6 million in Q2 2022.
• Historically, Income towards Parent Company has averaged -$30.3 million across 5 years, with a median of -$41.5 million in 2025.
• The largest YoY upside for Income towards Parent Company was 315.28% in 2025 against a maximum downside of 171.3% in 2025.
• Esperion Therapeutics' Income towards Parent Company stood at -$56.8 million in 2022, then fell by 1.02% to -$57.4 million in 2023, then jumped by 49.36% to -$29.1 million in 2024, then jumped by 315.28% to $62.6 million in 2025, then plunged by 142.14% to -$26.4 million in 2026.
• The last three Income towards Parent Company figures came in at -$26.4 million (Q1 2026), $62.6 million (Q4 2025), and -$32.0 million (Q3 2025), per Business Quant data.